Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 Receptor, in Subjects with Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 Receptor, in Subjects with Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs Edicotinib (Primary)
  • Indications Crohn's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PRINCE
  • Sponsors Provention Bio
  • Most Recent Events

    • 24 Oct 2018 Trial Design presented at the 26th United European Gastroenterology Week
    • 13 Aug 2018 According to a Provention Bio media release, top line data from this study is expected in the second half of 2019.
    • 26 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top